Cetuximab and panitumumab are monoclonal antibodies approved for the treatment of refractory CRC that block the epidermal growth factor receptor (EGFR) signaling pathway in tumor cells and, thus, can slow tumor progression [2]. This evidence concerns the gene EGFR and neoplasm.